<DOC>
	<DOCNO>NCT01342354</DOCNO>
	<brief_summary>This purpose study determine high tolerate dose Stereotactic Body Radiation Therapy ( SBRT ) also determine appropriate dose intact pancreatic cancer .</brief_summary>
	<brief_title>Study Stereotactic Body Radiation Therapy Patients With Intact Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Patients must histologically confirm , unresected cancer pancreas ampulla . The cancer may include invasive histology ( e.g . adenocarcinoma , neuroendocrine carcinoma ) . Patients must measurable radiographic disease.Patients previous complete resection eligible measurable radiographic disease clearly felt represent locally recurrent disease . Patients may receive number cycle chemotherapy prior treatment SBRT , within 2 week first fraction RT . Age &gt; = 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 3 month . Patients must normal organ marrow function . Ability understand willingness sign write informed consent document . Concurrent investigational therapy deliver period treatment observation ( 28 day postRT ) dose limit toxicity . Prior radiation therapy abdominal area would overlap proposed area treatment . Pregnancy . Primary disease &gt; 7.5 cm large diameter measure CT MRI . Gross extension tumor lumen duodenum . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Use bevacizumab vascular endothelial growth factor inhibitor chemotherapy within 3 month RT 6 month RT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Stereotactic Radiation</keyword>
</DOC>